{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:42:17Z","timestamp":1761093737881,"version":"build-2065373602"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.bcmd.2014.05.006","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T05:48:27Z","timestamp":1403675307000},"page":"110-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders"],"prefix":"10.1016","volume":"53","author":[{"given":"Flavia","family":"Stella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-4924","authenticated-orcid":false,"given":"Estela","family":"Pedrazzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgardo","family":"Baialardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorotea Beatriz","family":"Fantl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Schutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irma","family":"Slavutsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2014.05.006_bb0005","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","article-title":"Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3","volume":"117","author":"Dimopoulos","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0010","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0015","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.21913","article-title":"Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Rajkumar","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0025","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: report of the international myeloma workshop consensus panel 2","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/gcc.20109","article-title":"Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q","volume":"42","author":"Sawyer","year":"2005","journal-title":"Gene Chrom Cancer"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10245330512331390140","article-title":"Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma","volume":"10","author":"Shaughnessy","year":"2005","journal-title":"Hematology"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0040","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0045","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0050","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.humpath.2011.07.013","article-title":"Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed\/refractory multiple myeloma treated with bortezomib","volume":"43","author":"Chen","year":"2012","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0055","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2004-04-1319","article-title":"Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma","volume":"104","author":"Gutierrez","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/gcc.20231","article-title":"Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics","volume":"44","author":"Cremer","year":"2005","journal-title":"Gene Chrom Cancer"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0065","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1158\/1078-0432.CCR-08-0347","article-title":"Deletions of CDKN2C in multiple myeloma: biological and clinical implications","volume":"14","author":"Leone","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0070","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.leu.2402328","article-title":"Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis","volume":"16","author":"Kulkarni","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1747-1028-1-23","article-title":"Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs. increased expression","volume":"1","author":"Dib","year":"2006","journal-title":"Cell Div."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0080","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.2006.06325.x","article-title":"Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation","volume":"135","author":"Chang","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0085","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5858\/arpa.2012-0209-OA","article-title":"Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms","volume":"137","author":"Lu","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0090","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0960-9822(96)00741-5","article-title":"Cell cycle: reaching for a role for the Cks proteins","volume":"6","author":"Pines","year":"1996","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0095","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nrm1246","article-title":"Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover","volume":"4","author":"Reed","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0100","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrm1471","article-title":"The SCF ubiquitin ligase: insights into a molecular machine","volume":"5","author":"Cardozo","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0105","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0006-291X(03)00469-8","article-title":"High expression of Cks1 in human non-small cell lung carcinomas","volume":"303","author":"Inui","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0110","first-page":"305","article-title":"Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray","volume":"24","author":"Li","year":"2004","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0115","doi-asserted-by":"crossref","first-page":"R737","DOI":"10.1186\/bcr1278","article-title":"The expression of the ubiquitin ligase subunit Cks1 in human breast cancer","volume":"7","author":"Slotky","year":"2005","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0120","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00432-009-0582-8","article-title":"Overexpression of Cks1 is associated with poor survival by inhibiting apoptosis in breast cancer","volume":"135","author":"Wang","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0125","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/ijc.21660","article-title":"Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray","volume":"118","author":"Wong","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0130","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.humpath.2010.04.001","article-title":"Differential expression of CKS-1B in typical and blastoid variants of mantle cell lymphoma","volume":"41","author":"Akyurek","year":"2010","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0135","doi-asserted-by":"crossref","first-page":"e37433","DOI":"10.1371\/journal.pone.0037433","article-title":"Cks1 is required for tumor cell proliferation but not sufficient to induce hematopoietic malignancies","volume":"7","author":"Kratzat","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0140","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3324\/haematol.2010.022210","article-title":"CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma","volume":"95","author":"Chang","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0145","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0150","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","article-title":"Cks1b. Overexpressed in aggressive disease, regulates multiple myeloma growth and survival through skp2- and p27kip1-dependent and -independent mechanisms","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2010.05.002","article-title":"Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 gains","volume":"35","author":"Chang","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0160","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3324\/haematol.2011.046821","article-title":"Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma","volume":"97","author":"Kassambara","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment to multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0170","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0175","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0180","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0185","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0609.2008.01199.x","article-title":"Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients","volume":"82","author":"Bianchini","year":"2009","journal-title":"Eur. J. Haematol."},{"year":"2013","series-title":"An International System for Human Cytogenetic Nomenclature","author":"ISCN","key":"10.1016\/j.bcmd.2014.05.006_bb0190"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000329479","article-title":"New recurrent chromosome alterations in patients with multiple myeloma and plasma cell leukemia","volume":"134","author":"Stella","year":"2011","journal-title":"Cytogenet. Genome Res."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0200","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.beha.2007.08.004","article-title":"Genetic events in the pathogenesis of multiple myeloma","volume":"20","author":"Chng","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0205","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng","year":"2011","journal-title":"Leukemia"},{"year":"2014","series-title":"Mitelman Database of Chromosome Aberration in Cancer","key":"10.1016\/j.bcmd.2014.05.006_bb0210"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0215","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","article-title":"High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0220","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","article-title":"Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du My\u00e9lome","volume":"26","author":"Decaux","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0225","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/ajh.20998","article-title":"Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes","volume":"82","author":"Mohamed","year":"2007","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0230","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3109\/10428194.2010.524325","article-title":"Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone","volume":"51","author":"Chang","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0235","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.leukres.2013.09.025","article-title":"Genomic aberrations in anaplastic multiple myeloma: high frequency of 1q21(CKS1B) amplifications","volume":"37","author":"Bahmanyar","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0240","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/blood.V91.5.1732","article-title":"Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin","volume":"91","author":"Sawyer","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0245","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2009.07869.x","article-title":"Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon","volume":"147","author":"Sawyer","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0250","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.25775","article-title":"Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with Lenalidomide and Dexamethasone","volume":"117","author":"Klein","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0255","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1158\/1078-0432.CCR-11-1791","article-title":"Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival","volume":"17","author":"Boyd","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0260","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2013.088211","article-title":"Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no prognostic value","volume":"99","author":"An","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0265","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18632\/oncotarget.105","article-title":"Over-expression of CKS1B activates both MEK\/ERK and JAK\/STAT3 signaling pathways and promotes myeloma cell drug-resistance","volume":"1","author":"Shi","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0270","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ajh.23339","article-title":"Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles","volume":"88","author":"Mosca","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0275","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bbmt.2009.11.025","article-title":"Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy","volume":"16","author":"Nemec","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0280","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0285","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.V91.6.1873","article-title":"Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21","volume":"91","author":"Willis","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0290","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood.V95.9.2930.009k39_2930_2936","article-title":"MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma","volume":"95","author":"Gilles","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0295","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0002-9440(10)63276-2","article-title":"Overexpression of PDZK1 within the 1q12\u2013q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma","volume":"165","author":"Inoue","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0300","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/blood-2004-05-1760","article-title":"VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis","volume":"104","author":"Le Gouill","year":"2004","journal-title":"Blood"},{"issue":"s1","key":"10.1016\/j.bcmd.2014.05.006_bb0305","first-page":"S53","article-title":"Altered gene expression in multiple myeloma patients with gain of 1q21 locus","volume":"96","author":"Nemec","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0310","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/bmt.2009.107","article-title":"Reece D 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","volume":"45","author":"Chang","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0315","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2010.21","article-title":"Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma","volume":"24","author":"Chng","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0320","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.4049\/jimmunol.165.8.4346","article-title":"The expression of p18INK4 and p27kip1 cyclin-dependent kinase inhibitors is regulated differently during human B cell differentiation","volume":"165","author":"Schrantz","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0325","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hon.2018","article-title":"Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients","volume":"31","author":"Grzasko","year":"2013","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.bcmd.2014.05.006_bb0330","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.05.006_bb0335","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4161\/cc.6.7.4017","article-title":"Expression of cyclin-dependent kinase subunit 1 (Cks1) is regulated during the cell cycle by a CDE\/CHR tandem element and is downregulated by p53 but not by p63 or p73","volume":"6","author":"Rother","year":"2007","journal-title":"Cell Cycle"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979614000576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979614000576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:29:53Z","timestamp":1761049793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979614000576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S1079979614000576"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.05.006","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}